{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_15788", "batch_size": 200, "batch_pos": 162, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "'outbreaks' is a neutral term.", "method": "llm_batch", "batch_id": "batch_2_14828", "batch_size": 200, "batch_pos": 129, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb from the specified list paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_19408", "batch_size": 200, "batch_pos": 71, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment is a statement, not a question.", "method": "llm_batch", "batch_id": "batch_4_20584", "batch_size": 200, "batch_pos": 65, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "Lacks explicit calming language or keywords.", "method": "llm_batch", "batch_id": "batch_5_19136", "batch_size": 200, "batch_pos": 60, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_18748", "batch_size": 200, "batch_pos": 11, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_15872", "batch_size": 200, "batch_pos": 200, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes capability ('offers advantages in efficacy, speed of development and production, scalability, and reliability') without calming keywords.", "method": "llm_batch", "batch_id": "batch_8_14172", "batch_size": 200, "batch_pos": 1, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
